Brexucabtagene Autoleucel for Relapsed or Refractory MCL in Standard-of-Care Practice
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
J. Clin. Oncol 2023 Feb 08;[EPub Ahead of Print], Y Wang, P Jain, FL Locke, MJ Maurer, MJ Frank, JL Munoz, S Dahiya, AM Beitinjaneh, MT Jacobs, JP Mcguirk, JM Vose, A Goy, C Andreadis, BT Hill, KA Dorritie, OO Oluwole, A Deol, J Paludo, B Shah, T Wang, R Banerjee, DB Miklos, AP Rapoport, L Lekakis, A Ghobadi, SS Neelapu, Y Lin, ML Wang, MD JainFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.